GNRH1 and neoplasm: Both in vitro and in vivo data suggested that Pt-Mal-LHRH elicits tumor-targeted drug delivery with increased potency, efficacy, and a possible reduction in chemotherapeutic side effects allowing the use of a high dose of chemotherapy in patients compared to other platinum drugs.